LYON, France, April 10, 2008 (PRIME NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today that it has received Institutional Review Board (IRB) approval for Memorial Sloan-Kettering Cancer Center in New York City to participate in EDAP's ongoing Phase II/III clinical trial of Ablatherm(r)-High Intensity Focused Ultrasound (HIFU). The trial compares the outcomes of Ablatherm and Cryotherapy for the treatment of low-risk prostate cancer. This IRB approval brings the total number of active sites in the trial to 10 HIFU sites and 6 Cryotherapy sites.
